| Survival with axicabtagene ciloleucel in large B-cell lymphoma JR Westin, OO Oluwole, MJ Kersten, DB Miklos, MA Perales, A Ghobadi, ... New England Journal of Medicine 389 (2), 148-157, 2023 | 229 | 2023 |
| Development and validation of a novel acute myeloid leukemia–composite model to estimate risks of mortality ML Sorror, BE Storer, AT Fathi, AT Gerds, BC Medeiros, P Shami, ... JAMA oncology 3 (12), 1675-1682, 2017 | 173 | 2017 |
| Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation M Elsawy, ML Sorror Bone marrow transplantation 51 (10), 1283-1300, 2016 | 89 | 2016 |
| Multi‐centre validation of the prognostic value of the haematopoietic cell transplantation‐specific comorbidity index among recipient of allogeneic haematopoietic cell … M ElSawy, BE Storer, MA Pulsipher, RT Maziarz, S Bhatia, MB Maris, ... British journal of haematology 170 (4), 574-583, 2015 | 51 | 2015 |
| Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma M Elsawy, JC Chavez, I Avivi, JF Larouche, L Wannesson, K Cwynarski, ... Blood, The Journal of the American Society of Hematology 140 (21), 2248-2260, 2022 | 42 | 2022 |
| Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia ML Sorror, BE Storer, AT Fathi, A Brunner, AT Gerds, MA Sekeres, ... Blood, The Journal of the American Society of Hematology 138 (5), 387-400, 2021 | 34 | 2021 |
| Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/refractory large B-cell lymphoma JR Westin, FL Locke, M Dickinson, A Ghobadi, M Elsawy, T Van Meerten, ... Clinical Cancer Research 29 (10), 1894-1905, 2023 | 33 | 2023 |
| Intensive versus non-intensive induction therapy for patients (Pts) with newly diagnosed acute myeloid leukemia (AML) using two different novel prognostic models ML Sorror, BE Storer, M Elsawy, AT Fathi, AM Brunner, AT Gerds, ... Blood 128 (22), 216, 2016 | 31 | 2016 |
| Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by … A Lazaryan, M Dolan, MJ Zhang, HL Wang, MA Kharfan-Dabaja, DI Marks, ... haematologica 105 (5), 1329, 2019 | 30 | 2019 |
| Patterns of ruxolitinib therapy failure and its management in myelofibrosis: perspectives of the Canadian Myeloproliferative Neoplasm Group V Gupta, S Cerquozzi, L Foltz, C Hillis, R Devlin, M Elsawy, K Grewal, ... JCO oncology practice 16 (7), 351-359, 2020 | 26 | 2020 |
| Prognostic performance of the augmented hematopoietic cell transplantation-specific comorbidity/age index in recipients of allogeneic hematopoietic stem cell transplantation … M Elsawy, BE Storer, F Milano, BM Sandmaier, C Delaney, RB Salit, ... Biology of Blood and Marrow Transplantation 25 (5), 1045-1052, 2019 | 23 | 2019 |
| An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis AM Jimenez Jimenez, M De Lima, KV Komanduri, TP Wang, MJ Zhang, ... Bone marrow transplantation 56 (12), 3068-3077, 2021 | 17 | 2021 |
| Patient-reported outcomes in a phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel (axi-cel) versus standard of care therapy in patients … M Elsawy, JC Chavez, I Avivi, JF Larouche, L Wannesson, K Cwynarski, ... Blood 138, 430, 2021 | 15 | 2021 |
| “To combine or not to combine:” optimizing risk assessment before allogeneic hematopoietic cell transplantation M ElSawy, BE Storer, ML Sorror Biology of Blood and Marrow Transplantation 20 (9), 1455-1456, 2014 | 11 | 2014 |
| Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma. J Westin, OO Oluwole, MJ Kersten, DB Miklos, MA Perales, A Ghobadi, ... Journal of Clinical Oncology 41 (17_suppl), LBA107-LBA107, 2023 | 9 | 2023 |
| Impact of comorbidities at diagnosis of acute myeloid leukemia on one-year mortality ML Sorror, BE Storer, M Elsawy, AT Fathi, A Brunner, AT Gerds, ... Blood 126 (23), 532, 2015 | 9 | 2015 |
| Relative benefit for intensive versus non-intensive induction therapy for patients with newly diagnosed acute myeloid leukemia (AML) using a composite, age-comorbidity … M Sorror, B Storer, M Elsawy, A Fathi, A Brunner, A Gerds, M Sekeres, ... Haematologica 101, 221-222, 2016 | 8 | 2016 |
| Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy … J Westin, FL Locke, M Dickinson, A Ghobadi, M Elsawy, T van Meerten, ... Journal of Clinical Oncology 40 (16_suppl), 7548-7548, 2022 | 6 | 2022 |
| Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by … A Lazaryan, M Dolan, MJ Zhang, HL Wang, MA Kharfan-Dabaja, DI Marks, ... haematologica 106 (8), 2295-2296, 2021 | 6 | 2021 |
| Prognostic impact of comorbidities on outcomes of patients (pts) with relapsed or refractory large B-cell lymphoma (r/r LBCL) treated with chimeric antigen receptor T-cell … U Greenbaum, H Hashmi, M Elsawy, S Kim, A Moskop, FT Awan, ... Blood 140 (Supplement 1), 4636-4638, 2022 | 5 | 2022 |
